Kyntra drops mid-stage ADC, adding to years of stumbles
Kyntra Bio is discontinuing a mid-stage antibody-drug conjugate, the latest in a string of clinical and corporate setbacks for the company.
Kyntra Bio is the San Francisco biopharmaceutical company formerly known as FibroGen, focused on oncology and anemia therapies after a series of late-stage clinical and regulatory setbacks. Its HIF-PHI roxadustat is approved in several markets outside the United States.
Kyntra Bio is discontinuing a mid-stage antibody-drug conjugate, the latest in a string of clinical and corporate setbacks for the company.